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Abstract Rationale: Modulation of metabotropic gluta-
mate receptor (mGluR) subtypes represents a novel ap-
proach for the treatment of neurological and psychiatric
disorders. Objectives: This study was conducted to in-
vestigate the role of the mGluR5 and mGluR1 subtypes in
the modulation of pain and anxiety. Methods: ThemGluR5
antagonists, 2-methyl-6-(phenylethynyl)pyridine (MPEP)
and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP),
and the mGluR1 antagonist, (4-methoxy-phenyl)-(6-me-
thoxy-quinazolin-4-yl)-amine HCl (LY456236), were tested
in models of pain [mouse formalin test, rat spinal nerve
ligation (SNL)] and anxiety [Vogel conflict, conditioned
lick suppression (CLS)], and their efficacious effects were
compared to any associated side effects. Results: The
systemic administration of MPEP, MTEP, and LY456236
reduced hyperalgesia induced by formalin and mechanical
allodynia following SNL. However, only LY456236 com-
pletely reversed the allodynia. In the anxiety models, MPEP
(3–30 mg/kg), MTEP (3–10 mg/kg), and LY456236 (10–
30 mg/kg) produced anxiolytic-like effects similar to the
benzodiazepine, chlordiazepoxide (CDP, 6 mg/kg). How-
ever, only MPEP and MTEP were able to produce a level
of anxiolysis comparable to CDP. In a series of tests ex-
amining potential side effects, MPEP and MTEP reduced
body temperature and locomotor activity and impaired op-
erant responding for food and rotarod performance at
doses of 3–30 and 1–30 mg/kg, respectively. LY456236 re-
duced operant responding at 30 mg/kg. Conclusion: Both
mGluR5 and mGluR1 antagonists are effective in models
of pain and anxiety. However, an mGluR1 antagonist was
more efficacious than the two mGluR5 antagonists in the
pain models, which, conversely, appeared more efficacious
in the anxiety models. These findings support the potential
utility of mGluR5 and mGluR1 antagonists for both the
treatment of chronic pain and as novel anxiolytics.
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Introduction
The ability of glutamate to act on a large number of
receptors provides opportunities to modulate the activity
of glutamatergic synapses and to potentially treat disorders
that involve alterations in glutamatergic neurotransmis-
sion. Glutamate synaptic responses in the central nervous
system (CNS) are mediated via the activation of two
families of receptors: ligand-gated cation channels termed
ionotropic glutamate receptors and G-protein-coupled re-
ceptors known as metabotropic glutamate receptors or
mGluRs. Thus far, eight mGluR subtypes, together with
splice variants, have been cloned and characterized in func-
tional studies (Schoepp et al. 1999). The eight mGluRs are
grouped into three classes based on structural homology,
pharmacology, and signal transduction mechanisms: group
I receptors (mGluRs 1 and 5) are coupled to phospholipase
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C and stimulate phosphoinositide hydrolysis and intracel-
lular Ca2+ signal transduction, whereas group II and group
III receptors are negatively coupled to adenyl cyclase
(Nakanishi 1994; Conn and Pin 1997). Among these re-
ceptors, the recent identification of noncompetitive group I
subtype-specific antagonists has greatly accelerated the
investigation and the elucidation of the role of mGluR1 and
mGluR5 in animal models of neurological and psychiatric
disorders.
A number of behavioral (Fisher and Coderre 1998;
Fundytus et al. 1998; Bhave et al. 2001; Dolan and Nolan
2002; Dolan et al. 2003) and electrophysiological (Young
et al. 1994, 1997) studies have demonstrated a specific
role for group I mGluRs in nociceptive processing in the
CNS, including mechanisms of hyperalgesia and inflam-
mation. mGluR1 appears to be localized primarily on
postsynaptic elements throughout the dorsal and ventral
horns of the spinal cord (Neugebauer 2001). Behavioral
studies have demonstrated that intrathecal administration
of the mGluR1 antagonist, CPCCOEt, produces antinoci-
ceptive effects in the second phase of formalin-induced
nociceptive behavior (Neugebauer 2001). Additionally,
expression of mGluR1 is increased in rats following spinal
cord injury, and this may mediate the chronic central pain
induced by the injury (Mills and Hulsebosch 2002).
Knockdown of spinal mGluR1 by intrathecal infusion of
antisense oligonucleotides attenuated cold hyperalgesia
and mechanical allodynia in neuropathic rats (Fundytus
et al. 2001, 2002). Additionally, spinal administration of
anti-mGluR1 IgG antibodies reduced cold hyperalgesia, but
not mechanical allodynia, in neuropathic rats (Fundytus
et al. 1998). The critical role of spinal mGluR1 receptors
in pain-related central sensitization is emphasized at the
single cell level by electrophysiological in vivo studies
in anesthetized animals. Intraspinal administration of the
mGluR1 antagonist, 1-aminoindan-1,5-dicarboxylic acid
(AIDA), inhibited the responses of primate spinothalam-
ic tract neurons to brief, noxious, but not innocuous,
mechanical cutaneous stimuli, as well as central sensi-
tization in the capsaicin pain model (Neugebauer et al.
1999). In rats with knocked down mGluR1 expression,
the responses of multireceptive dorsal horn neurons to
noxious input evoked by repeated topical applications of
the C-fiber irritant mustard oil were significantly re-
duced compared to control neurons; the responses to
innocuous cutaneous stimuli were unaffected (Young et al.
1998).
mGluR5 receptors are expressed both pre- and post-
synaptically in the superficial dorsal horn on the spinal cord
(Neugebauer 2001). Similar to mGluR1, the intrathecal
administration of the mGluR5 antagonist 2-methyl-6-
(phenylethynyl)pyridine (MPEP) produced antinociceptive
effects in the second phase of the formalin model (Karim et
al. 2001), and the spinal administration of anti-mGluR5
IgG antibodies reduced cold hyperalgesia in neuropathic
rats (Fundytus et al. 1998). Recent studies also demon-
strated the attenuating effects of systemically administered
MPEP on nociceptive behavior in neuropathic pain models
(Walker et al. 2001a,b; Fisher et al. 2002; Hudson et al.
2002). Finally, electrophysiological recordings in a hemi-
sected spinal cord in vitro preparation suggest that mGluR5
receptors may be involved in brief and prolonged spinal
nociception (Bordi and Ugolini 2000). Clearly, the mGluR5
receptor subtype has a role in the modulation of pain, but the
current evidence is perhaps not as strong as for mGluR1.
The predominant expression of mGluR5 in areas of the
mammalian brain thought to be involved in emotional
processes has suggested a possible role in affective dis-
orders, especially stress and anxiety (see Bordi and
Ugolini 1999 for review). Several reports describing the
effects of mGluR5 antagonists in various animal models
provide compelling evidence for a broad anxiolytic-like
activity of mGluR5 antagonists (Klodzinska et al. 2000;
Spooren et al. 2000; Schulz et al. 2001; Tatarczynska et al.
2001; Brodkin et al. 2002a). The anxiolytic-like effects of
mGluR5 antagonists, particularly MPEP (Gasparini et al.
1999), have been demonstrated in both rats and mice
across a range of commonly used models. Specifically,
mGluR5 antagonists produce anxiolytic-like effects in
unconditioned response models, including the elevated
plus maze, stress-induced hyperthermia, and Vogel con-
flict tests, and conditioned response models, such as fear-
potentiated startle, a conditioned ultrasonic vocalization
(USV) procedure, and the Geller–Seifter test (Klodzinska
et al. 2000; Spooren et al. 2000; Schulz et al. 2001;
Tatarczynska et al. 2001; Brodkin et al. 2002a). Encour-
agingly, the anxiolytic-like effects of mGluR5 antagonists
appear to be in the magnitude of the benzodiazepine an-
xiolytics, but with an improved side-effect profile. Ad-
ditionally, in support of the role of mGluR5 in stress and
anxiety, Brodkin et al. (2002b) demonstrated that the
mGluR5 knockout mouse had a reduced hyperthermic re-
sponse to stressful stimuli. Unlike mGluR5, very little is
known about the anxiolytic potential of mGluR1 antago-
nists, although a recent report from Klodzinska et al.
(2004a) demonstrated the anxiolytic-like effects of the
selective mGluR1 antagonist, AIDA, and a reduced pro-
pensity to induce the side effects characteristic of
benzodiazepines.
Given this evidence, and, as to our knowledge, no studies
have directly compared the profile of mGluR5 and mGluR1
antagonists in pain and anxiety, the aim of this study was to
test the available pharmacological tools in representative
animal models. Specifically, the noncompetitive mGluR5
antagonists 2-methyl-6-(phenylethynyl)pyridine (MPEP;
Gasparini et al. 1999) and 3-[(2-methyl-1,3-thiazol-4-yl)
ethynyl]pyridine (MTEP; Anderson et al. 2002), and the
noncompetitive mGluR1 antagonist, (4-methoxy-phenyl)-
(6-methoxy-quinazolin-4-yl)-amine HCl (LY456236; Barton
et al. 2003), were used. Although a significant number of
studies have used MPEP as a standard antagonist (Karim
et al. 2001;Walker et al. 2001a,b; Fisher et al. 2002; Hudson
et al. 2002), to date, no work has been published on MTEP
or LY456236. From the available literature, the reported
affinities (Ki values) of MPEP and MTEP at rat mGluR5
receptors are 12 and 16 nM, respectively (Cosford et al.
2003). From our in vitro studies, LY456236 had an in vitro
affinity of 143 nM at rat mGluR1 receptors (measured by
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displacement of [3H]R214127 binding in rat membranes
as described by Lavreysen et al. 2003). Compound se-
lectivity within the mGluR family was also confirmed using
assays employing nonneuronal cell lines (HEK293) stably
expressing recombinant human mGluR1a, mGluR5b,
mGluR2, and mGluR8. Up to concentrations of 10 mM,
MPEP and MTEP were devoid of activity at human
mGluR1a, mGluR2, and mGluR8a, and LY456236 had no
effect on human mGluR5b, mGluR2, and mGluR8a
(measured by Ca2+ flux assay). In these studies, MPEP,
MTEP, and LY456236 were tested in a number of es-
tablished rodent models of pain, as well as models sensitive
to anxiolytic drugs. Although a number of publications
have described the effects of mGluR1 or mGluR5
antagonists in models of pain or models sensitive to anxio-
lytic drugs (Neugebauer et al. 1999; Bordi and Ugolini
2000; Dogrul et al. 2000; Klodzinska et al. 2000, 2004a;
Spooren et al. 2000; Neugebauer 2001), to our knowledge,
this is the first study to directly compare these classes of
mGluR antagonists in both sets of assays. Additionally,
MPEP, MTEP, and LY456236 were tested in a set of be-
havioral assays that assessed neurological function (motor
coordination, body temperature, response rate) in order
to evaluate the efficacy and side-effect profiles of these
mGluR antagonists, which, again, have not been directly
compared in the same study.
Materials and methods
Subjects
Male CD1 mice weighing 25–30 g and male CD rats
weighing 150–175 g (Charles River, Calco, Italy) were
used in the formalin and spinal nerve ligation (SNL)
experiments, respectively. Male CD rats (Charles River,
Kingston, NY, USA) weighing 225–250 g were used for
the remaining studies. Mice were housed ten per cage,
whereas rats were housed singly [conditioned lick sup-
pression (CLS) and fixed-ratio (FR) studies—see below]
or three per cage (all other studies), under a 12 h light–
dark cycle (lights on 0700 h) with constant temperature
and humidity. Throughout the studies, animals were given
free access to food (except during the FR studies) and
water (except during Vogel and CLS studies). Rats were
used once only, i.e., for a single administration of drug or
vehicle (except in the SNL, CLS and FR assays—see
below). All studies took place during the light cycle
between 0800 and 1700 h. All surgical and testing
procedures involving animals and their care were con-
ducted in conformity with the institutional guidelines and
in compliance with the European Community Council
Directive 86/609 (OJ L 358, 1, December 12, 1987), the
NIH’s Guide to the Care and Use of Laboratory Animals,
and the Animal Welfare Act.
Mouse formalin test
Mice were gently restrained and 30 μl of formalin solution
(1.5% in saline) was injected subcutaneously into the
plantar surface of the right hind paw of the mouse, using a
microsyringe with a 27-gauge needle. After the formalin
injection, the mouse was immediately placed into a Plex-
iglas observation box (30×20×20 cm), and the nociceptive
response of the mouse to the formalin injection was
observed for a period of 60 min. The duration of licking
and flinching of the injected paw was recorded and
quantified every 5 min for the total observation period.
The recording of the early phase (first phase) started
immediately and lasted for 5 min. The late phase (second
phase) started 10–15 min after formalin injection. The
period 15–30 min after formalin injection was used for
pharmacological studies since this period incorporates the
peak formalin effect.
L5 and L6 spinal nerve ligation of the rat sciatic nerve
Peripheral neuropathy was produced by ligating the L5
and L6 spinal nerves of the right sciatic nerve, according
to the method previously described by Kim and Chung
(1992). Briefly, rats were anaesthetized with chloral hy-
drate (400 mg/kg, i.p.), placed in a prone position, and the
right paraspinal muscles were separated from the spinal
processes at the L4–S2 levels. The L5 transverse process
was carefully removed with a small rongeur to identify the
L4–L5 spinal nerves. The right L5 and L6 spinal nerves
were isolated and tightly ligated with 7–0 silk thread. A
complete hemostasis was confirmed and the wound was
sutured.
Measurement of tactile allodynia
Tactile sensitivity was evaluated using a series of cal-
ibrated Semmes-Weinstein (Stoelting, IL) von Frey fila-
ments, with a bending force ranging from 0.25 to 15 g.
Rats were placed in a transparent plastic box endowed
with a metal mesh floor and were habituated to this
environment prior to testing. The von Frey filaments were
applied perpendicularly to the midplantar surface of the
ipsilateral hind paws, and the mechanical allodynia was
determined by sequentially increasing and decreasing the
stimulus strength (“up–down” procedure of filament pre-
sentation). The 50% paw withdrawal threshold was de-
termined by the nonparametric Dixon test (Chaplan et al.
1994). Paw licking and vigorously shaking after stimulation
were considered pain-like responses. Only those rats that
demonstrated a threshold less than 4 g (commonly con-
sidered in the literature as the tactile allodynia threshold) on
postoperative day 14 were included in the behavioral stud-
ies (more than 90% of the animals). Compounds were
tested using within-subjects studies such that each rat
received vehicle and all doses of a compound in a random,
crossover design.
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Vogel conflict
Testing took place in eight standard operant conditioning
boxes (32×25×25 cm) (Med Associates, Camden, VT).
Each box contained a stainless-steel drinking spout that
protruded through the center of the front wall 3 cm above
the floor. The drinking spout was connected to a 200-ml
bottle containing 0.2% saccharin solution. Each box was
located within a ventilated and sound-attenuated chamber
containing a 5-W house light. Licks were recorded
automatically by a lickometer connected to a computer.
Scrambled foot shock (0.4 mA, 500-ms duration) was
delivered to the spout and grid floor of the box upon
completion of every 20th lick. Prior to any testing in the
boxes, rats were deprived of water for ∼20 h. Additionally,
the day before drug testing, rats were placed into the boxes
and allowed free, unpunished access to the saccharin
solution for 10 min to establish a robust baseline level of
licking. On the test day, rats were brought to the test room
and allowed to acclimate for 1 h. Drug or vehicle was
administered, and, following an appropriate pretreatment
time, rats were placed into the boxes and the numbers of
licks during a 10 min test session were recorded.
Conditioned lick suppression
Experiments took place in the Vogel conflict apparatus. A
cohort of 60 rats was water-deprived for 20 h and trained
under a schedule of CLS. Briefly, rats were presented with
20 trials, each consisting of 23 s of unpunished drinking,
followed by 7 s in which a tone was delivered. Licks
during the first 2 s of tone were unpunished, whereas licks
during the final 5 s were punished with scrambled shock
delivery (0.7 mA, 500-ms duration). Rats were trained
under this schedule 6 days per week until they made fewer
than 5% of total licks during the period in which tone was
presented. When rats had reached this criterion, they were
tested during a session in which tone was presented but
shock delivery was turned off. If rats made less than 5% of
total licks during the tone period under these conditions,
they were deemed to be conditioned and suitable for drug
testing. On the day of testing, rats were brought to the test
room and administered vehicle or a dose of drug. After an
appropriate pretreatment, rats were placed into the appa-
ratus, and the number of licks during both the unpunished
(no tone) and punished (tone, no shock) components of the
test was recorded for 20 trial presentations. The drug was
administered using a within-subjects, crossover design
such that the effect of vehicle administration and up to five
doses of drug [including a maximal effective 6 mg/kg dose
of the positive control, chlordiazepoxide (CDP)] was
assessed over several different test sessions. The drugs
were tested no more than twice a week. On intervening
days, rats continued to be trained in sessions with both
tone and concomitant shock. Rats received one or two of
the drugs tested in these studies with sufficient washout
between testing.
Body temperature
A rectal probe and a digital thermometer (Physitemp,
Clifton, NJ) were used to measure core body temperature in
rats. The probe was lubricated with mineral oil and inserted
into the rectum. Body temperature was recorded prior to
injection (mean baseline temperature: MPEP=36.8°C;
MTEP=36.8°C; LY456236=37.3°C) and every 30 min
following injection for 3 h. For brevity, only data from the 2
h reading (the time when the maximum effect was ob-
served) were analyzed for each drug.
Locomotor activity
Rats were transferred from their home cages to an anteroom
in which they were allowed to habituate for 1 h. Following
dosing and the appropriate pretreatment time, activity levels
were recorded for 2 h using a Versamax LMA system
(Accuscan Instruments, Columbus, OH). Each monitoring
system consisted of a Plexiglas box (height 30 cm, width 42
cm, length 42 cm), and activity was monitored by xy-axis
photobeams located 2 cm above the floor and spaced 2.5 cm
apart, which sampled 100 times per second. Data were
transferred to a computer that digitized and stored the data
for separate analysis.
Rotarod
Rats were pretrained to a performance criterion on a rotarod
(Ugo Basile: rod width 8.5 cm, diameter 7 cm) 24 h prior to
testing. Rats were required to remain on the rod rotating at
16 rpm for 120 s during two successive trials (>95% of
animals attained this criterion). On test day, rats were tested
in six trials, three each at 8 and 16 rpm. The duration on the
rod was recorded up to a maximum of 120 s, and only the
best trial at each speed was used in the final analysis.
Beam walking
Rats were pretrained to a performance criterion of suc-
cessfully traversing the beam (length 90 cm, width 2 cm,
elevation 43 cm) in order to enter a dark box within 60 s
without any foot slips, twice during both morning and
afternoon training sessions (>95% of animals attained this
criterion). On test day, each rat was given two trials on the
beam. The distance traversed along the beam was re-
corded, and the best performance out of the two trials was
recorded and used in the final analysis.
Fixed-ratio responding
Studies were conducted in 12 operant conditioning boxes
housed in sound-attenuating chambers (MED Associates,
Georgia, VT). Rats were trained to lever press for 45 mg
food pellets (Bio-Serv, Frenchtown, NJ). To maintain
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motivation, rats were kept at 80% of their normal free-
feeding body weight. Training began at an FR schedule of
reinforcement of 1 (FR1, i.e., one lever press is required to
obtain one food pellet), and the FR was gradually in-
creased to FR10 (ten lever presses per pellet). Sessions
lasted either 60 min or until a rat had received 100 pellets,
whichever occurred first. Specially designed software
controlled the boxes, ran the FR program, and collected
the data (KESTREL system, Conclusive Solutions, Cam-
bridge, UK). Drugs were tested in a within-subjects,
crossover-designed study such that each rat served as its
own control. Rats received one or two of the drugs tested
in these studies with sufficient washout between testing.
Drugs
Formalin was prepared by diluting a formaldehyde so-
lution (37%, Scharlau, Barcelona, Spain) with saline to a
final concentration of 1.5%. MPEP hydrochloride, MTEP
hydrochloride, and LY456236 were synthesized by the
Medicinal Chemistry Department of the Schering Plough
Research Institute. Chlordiazepoxide hydrochloride was
purchased from Sigma-Aldrich (St. Louis, MO). MPEP,
MTEP, and LY456236 were dissolved in a 10% Tween
80/90% distilled water vehicle, and CDP was dissolved in
0.9% saline. All drugs were administered by the intra-
peritoneal (i.p.) route at volumes of 1 ml/kg (rat) or 10 ml/
kg (mouse), and all doses are expressed as free base.
Statistical analysis
Data from the mouse formalin test were expressed as the
area under the curve (AUC) for the 15- to 30 min period
(second phase). Data were analyzed using a one-way
analysis of variance (ANOVA). In the SNL studies, the
force elicited by the von Frey filaments was expressed in
grams (g) and analyzed using a repeated-measures
ANOVA with treatment as the within-subjects factor. In
the Vogel conflict test, total licks were analyzed using a
one-way ANOVA with treatment as the between-subjects
factor. In the CLS studies, drug effects on both punished
and unpunished licking were analyzed using a repeated-
measures ANOVA with drug treatment as the within-
subjects factor. In the side-effect studies, total distance
traveled [locomotor activity (LMA)], time on the rotarod
(at both rpm rates), beam walking performance (distance
traversed), and body temperature (2 h post-injection) were
analyzed using one-way ANOVAs with treatment as the
between-subjects factor. Response rate in the FR studies
was analyzed using a repeated-measures ANOVA with
treatment as a within-subjects factor. In all studies, the
significance level for effects of drug was p<0.05, and data
were analyzed post hoc using Dunnett’s test.
Results
Mouse formalin test
MPEP (3–30 mg/kg) and MTEP (1–30 mg/kg) reduced the
formalin effect, with MPEP having significant effects at 10
and 30 mg/kg [F(3,31)=33.0, p<0.01] and MTEP at 3–30
mg/kg [F(4,38)=5.9, p<0.01]. The 30 mg/kg doses of
MPEP and MTEP were also effective during the first phase
of the formalin effect, reducing the nociceptive behavior by
20 and 30%, respectively (vehicle=198±12 s, MPEP=160
±11 s, MTEP=140±11 s). In contrast, the mGluR1 receptor
antagonist, LY456236 (10–100 mg/kg), had no effect
on the first phase of the response (vehicle=203±11 s,
LY456263=220±12 s). However, LY456236 was effec-
tive in reducing the second phase response significantly
at 30 and 100 mg/kg (Fig. 1) [F(3,30)=17.7, p<0.01].
Spinal nerve ligation
MPEP (10–30 mg/kg) dose-dependently increased ligated
side withdrawal threshold, compared to the vehicle-treated
group [F(24,252)=1.6, p<0.05] (Fig. 2), with a significant
increase at 30 mg/kg, which had a peak effect at 30 min
and slowly returned to control values within 90 min.
MTEP (1–10 mg/kg) produced a dose-dependent increase
in withdrawal threshold [F(24,252)=1.6, p<0.05] with a
significant effect at 10 mg/kg (Fig. 2), with a peak effect at
60 min. LY456236 (1–10 mg/kg) also increased with-
drawal threshold with the 10 mg/kg dose producing a
significant antiallodynic effect [F(8,76)=4.9, p<0.01]
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Fig. 1 Antihyperalgesic effect of the mGluR5 antagonists, MPEP
and MTEP, and the mGluR1 antagonist, LY456236, in the formalin
test in mice. Formalin (1.5%; 30 μl) was injected subcutaneously
into the plantar surface of the right hind paw of the mouse. Time
spent licking and flinching the paw was considered a measure of
nociceptive intensity. Bars represent the area under the curves for
the second phase, calculated from 15 to 30 min after formalin
injection. Data are mean±SEM of eight to 12 animals per group.
*p<0.05 and **p<0.01 vs vehicle (solid bar)
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remaining above control values for at least 60 min (Fig. 2).
The antiallodynic effects of MPEP and MTEP did not
reach the naive threshold (15 g) or at least the contralateral
side threshold (Fig. 2). On the contrary, LY456236 com-
pletely reversed the allodynia, restoring the threshold to
near-naive threshold and above the threshold of the
contralateral paw (Fig. 2).
Vogel conflict
MPEP [F(3,34)=28.7, p<0.01] and MTEP [F(3,67)=8.0,
p<0.01] produced anxiolytic-like increases in licking in the
Vogel conflict test at 3 and 10 mg/kg (Fig. 3). In both
studies, the anxiolytic-like effects of MPEP and MTEP
reached the level achieved by the benzodiazepine control,
CDP (vehicle=150±27 licks, 1mg/kg=186±35, 3mg/kg=269
±59, 10 mg/kg=627±134). LY456236 also produced an
anxiolytic-like increase in licking [F(3,31)=4.6, p<0.01]
with a significant effect at 10 mg/kg (Fig. 3). At 30 mg/kg,
LY456236 appeared to reduce licking, suggesting that some
secondary behavioral effect may be influencing the rats.
Conditioned lick suppression
MPEP and MTEP produced anxiolytic-like increases in
licking during the punished phase in the CLS test (Fig. 4).
MPEP increased punished licking [F(4,56)=8.0, p<0.01]
with a trend at 10 mg/kg and a significant effect at 30 mg/
kg; similarly, MTEP increased licking [F(4,44)=18.0,
p<0.01] with a trend at 1 mg/kg and significant effects at
3 and 10 mg/kg. MPEP and MTEP had no effect on
unpunished licking (Table 1). LY456236 increased pun-
ished licking [F(3,45)=6.1, p<0.01] with a significant effect
at 30 mg/kg; however, this dose also reduced unpunished
licking (Table 1) suggesting that LY456236 may be af-
fecting responding. In all studies, the positive control, CDP
(6 mg/kg), increased punished licking (Fig. 4). CDP re-
duced unpunished licking in all three studies (Table 1),
possibly due to its sedative effects. Finally, on an important
note, while MPEP and MTEP were able to achieve efficacy
of the magnitude of CDP, LY456236 only increased pun-
ished licking to ∼50% of the CDP response.
Body temperature
MPEP and MTEP significantly reduced body temperature
(Table 2), and these reductions were evident 30 min after
treatment and persisted for at least 3 h (the maximum length
of our study). For brevity, only the body temperature 2 h
after injection was analyzed statistically as the maximum
effect was observed at this time point. At this time point,
MPEP [F(4,54)=18.0, p<0.01] and MTEP [F(5,59)=56.0,
p<0.01] significantly reduced body temperature at doses of
10–100 mg/kg (Table 2). In the same design of study,
LY456236 had no effect on body temperature (Table 2) up
to a dose of 30 mg/kg, across the 3 h test.
Locomotor activity
MPEP [F(4,45)=4.0, p<0.01] and MTEP [F(5,66)=5.7,
p<0.01] reduced LMA in terms of the total distance
traveled with significant reductions at 100 and 10–100 mg/
kg, respectively (Table 2). LY456236 had no effect on
LMA up to a dose of 30 mg/kg (Table 2).
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Fig. 2 Antiallodynic effects of mGluR5 antagonists, MPEP and
MTEP, and mGluR1 antagonist, LY456236, in L5–L6 spinal nerve
ligated rats. Data are mean±SEM of eight to 20 rats and represent
the 50% response threshold calculated for each rat. *p<0.05 and
**p<0.01 vs vehicle
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Rotarod
MPEP significantly reduced rotarod performance at both
the 8 rpm [F(4,50)=6.6, p<0.01] and 16 rpm [F(4,50)=4.7,
p<0.01] speeds. The 30 mg/kg dose reduced performance
at 16 rpm, and the 100 mg/kg dose reduced performance at
both 8 and 16 rpm (Table 2). MTEP significantly reduced
rotarod performance at doses of 30 and 100 mg/kg at both
the 8 rpm [F(5,54)=4.0, p<0.01] and 16 rpm [F(5,54)=8.5,
p<0.01] speeds (Table 2). LY456236 had no effect on
rotarod performance up to a dose of 30 mg/kg (Table 2).
Beam walking
MPEP had no effect on the distance traversed, but MTEP
significantly reduced this measure [F(5,54)=3.2, p=0.01]
at a dose of 100 mg/kg (Table 2). LY456236 had no effect
up to a dose of 30 mg/kg (Table 2).
Fixed-ratio responding
MPEP [F(3,33)=31.0, p<0.01] and MTEP [F(3,44)=9.9,
p<0.01] reduced responding in the FR assay with sig-
nificant reductions at doses of 10–30 and 1–10 mg/kg,
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Fig. 3 Anxiolytic-like effects of the mGluR5 antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in the rat Vogel
conflict test. Data are mean±SEM of 8 to 19 rats and represent the mean number of licks for each rat. *p<0.05 and **p<0.01 vs vehicle
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Fig 4 Anxiolytic-like effects of the mGluR5 antagonists, MPEP
and MTEP, and the mGluR1 antagonist, LY456236, in the rat
conditioned lick suppression (CLS) test. Data are mean±SEM of 12–
16 rats and represent the mean number of punished licks for each rat.
This study was of a within-subjects design such that each rat served
as its own control. *p<0.05 and **p<0.01 vs. vehicle. CDP was
included as a positive control and tested at a maximal effective dose
of 6 mg/kg
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respectively (Table 2). LY456236 reduced responding
[F(3,27)=8.5, p<0.01] at a dose of 30 mg/kg (Table 2).
Discussion
Amajor aim of these studies was to test the effects of group
I mGluR antagonists in models of pain and models sen-
sitive to anxiolytic drugs. Specifically, the mGluR5 antag-
onists, MPEP and MTEP, and the mGluR1 antagonist,
LY456236, were administered systemically and tested in
the acute pain formalin model in mice and the allodynic
spinal nerve ligation model in rats. Furthermore, all three
drugs were tested in two models sensitive to the effects of
clinically used anxiolytic drugs: Vogel conflict and condi-
tioned lick suppression.
We first demonstrated that mGluR5 and mGluR1 an-
tagonists exhibit robust analgesic effects in the mouse for-
malin test, a nociceptive model that presents both acute
(early phase) and chronic (second phase) nociceptive con-
ditions. MPEP, MTEP, and LY456236 dose-dependently
reduced the amount of licking and flinching following
intraplantar formalin injection including effects during the
second phase of the response. Furthermore, the three an-
tagonists reduced hyperalgesia by a similar magnitude.
These results are consistent with previous studies that have
implicated both mGluR5 and mGluR1 in mediating the
noxious effects of formalin (Bhave et al. 2001; Zhou et al.
2001; Noda et al. 2003). Therefore, our findings support the
potential utility of group I mGluR antagonists as analgesics
for chronic pain.
Additionally, using the rat SNL model, we demonstrated
that MPEP, MTEP, and LY456236 reduced the develop-
ment of mechanical allodynia. These data support the role
of group I mGluRs in mediating aspects of chronic, neu-
ropathic pain (Fundytus et al. 1998, 2001; Hofmann et al.
2001) and are consistent with findings from previous stud-
ies (Dogrul et al. 2000; Yashpal et al. 2001; Sotgiu et al.
Table 1 Effects of the mGluR5 antagonists, MPEP and MTEP, and
the mGluR1 antagonist, LY456236, on unpunished licking during
the rat conditioned lick suppression (CLS) test
Dose (mg/kg) MPEP MTEP LY456236
0 515±141 428±81 357±103
0.3 NT 410±81 NT
1 536±99 505±122 NT
3 433±97 548±91 264±54
10 344±59 536±94 262±58
30 465±130 NT 135±25*
CDP 6 228±41** 321±72 280±60
Chlordiazepoxide (CDP) was included as a positive control in each
CLS test and was tested at a maximal effective dose of 6 mg/kg
NT Not tested
* p<0.01 vs vehicle (0 mg/kg)
** p<0.05 vs vehicle
Table 2 Effects of the mGluR5 antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, on body temperature, locomotor
activity (distance traveled), rotarod and beam walking performance, and fixed-ratio (FR) responding in the rat
Drug dose (mg/kg) Body temperature (°C) Distance traveled (cm) Rotarod Beam walk (cm) FR responding
8 rpm 16 rpm
MPEP
0 37.5±0.1 2,634±536 117±3 110±8 85±5 1.26±0.06
3 37.1±0.2 1,672±254 120±0 112±5 90±0 1.22±0.07
10 36.7±0.1* 1,371±553 120±0 110±7 83±7 0.77±0.07*
30 36.6±0.1* 1,411±377 111±8 79±11** 90±0 0.62±0.09*
100 35.6±0.3* 496±92* 80±12* 64±16* 85±4 NT
MTEP
0 37.3±0.1 3,695±586 120±0 120±0 90±0 1.03±0.13
1 37.4±0.1 3,408±559 112±7 110±10 90±0 0.73±0.10**
3 37.0±0.1 2,422±278 114±6 98±12 90±0 0.58±0.08*
10 36.7±0.1** 2,048±582** 110±7 94±13 81±8 0.32±0.05*
30 35.2±0.3* 2,087±225** 89±12** 57±13* 90±0 NT
100 33.1±0.4* 1,393±139* 71±13* 31±11* 70±6* NT
LY456236
0 37.3±0.2 1,572±214 118±2 93±13 90±0 1.18±0.12
3 37.5±0.1 1,818±333 120±0 110±7 90±0 1.26±0.14
10 37.4±0.2 1,155±233 120±0 112±7 90±0 1.09±0.12
30 37.5±0.1 1,811±204 109±11 101±10 90±0 0.71±0.12*
MPEP: n=11–12 (body temperature), 10 (LMA), 11 (rotarod), 11 (beam walk), 12 (FR); MTEP: n=10–11 (body temperature), 12 (LMA), 10
(rotarod), 10 (beam walk), 12 (FR); LY456236: n=10 (body temperature), 12 (LMA), 10 (rotarod), 10 (beam walk), 10 (FR)
NT Not tested
* p<0.01 vs vehicle (0 mg/kg)
** p<0.05 vs vehicle
214
2003; Urban et al. 2003). Interestingly, only LY456236
was able to completely attenuate the allodynic response
back to control levels. While MPEP and MTEP were able
to attenuate the effects of SNL, neither compound was able
to completely reverse the allodynia. These findings support
the idea that mGluR1 and mGluR5 have differential roles
in mediating nociceptive responses (Neugebauer et al.
2003; Li and Neugebauer 2004). Therefore, based on our
comparative studies, mGluR1 antagonists may be more
effective than mGluR5 antagonists in treating neuropathic
pain, although further studies with a broader range of
compounds are warranted to confirm this.
In the second part of these studies, MPEP, MTEP, and
LY456236 were tested in two models sensitive to anxio-
lytic drugs based on studies that have implicated both
mGluR5 and mGluR1 in anxiety disorders and have
suggested that mGluR5 (Klodzinska et al. 2000; Spooren
et al. 2000; Tatarczynska et al. 2001; Schulz et al. 2001;
Brodkin et al. 2002a; Pilc et al. 2002) and mGluR1
antagonists (Klodzinska et al. 2004a) may represent novel
anxiolytic-like drugs with a reduced propensity to induce
benzodiazepine-like side effects. Our studies confirmed
the potent anxiolytic-like effect of MPEP in the Vogel
conflict model (see Tatarczynska et al. 2001; Pilc et al.
2002) at doses that are known to bind to the mGluR5
receptor (Anderson et al. 2002). Further, we extended this
finding to the structurally related mGluR5 antagonist,
MTEP (see also Klodzinska et al. 2004b), which produced
a significant anxiolytic-like effect in this model and, ad-
ditionally, appeared to be slightly more potent than MPEP.
Given the similar in vitro binding affinity for MPEP and
MTEP at the mGluR5 receptor, the increased in vivo
potency of MTEP may be due to an improved pharma-
cokinetics profile, for example, improved bioavailability
and/or brain penetration. Importantly, the anxiolytic-like
effects of MPEP and MTEP in the Vogel conflict model
were similar in magnitude to the benzodiazepine CDP. The
anxiolytic-like effects of MPEP and MTEP were also
observed in the CLS model, a conditioning model similar
to the Vogel that requires the rat to suppress licking
behavior during the presentation of a light cue previously
associated with mild foot shock. In the CLS test, MPEP
and MTEP produced a robust increase in licking during
the punishment phase, and again, the magnitude of effect
was similar to that seen with a maximally effective dose of
CDP. Importantly, although shock is initially used to
condition the rats in the CLS test, no shock is presented
during the “punished phase” of the test. Therefore, the
anxiolytic-like effects of MPEP and MTEP were not due
to any potential analgesic effect. Additionally, we have
tested the mu opioid agonist, morphine, in both the Vogel
and CLS assays, and it was ineffective at analgesic doses
(data not shown). Therefore, in line with previous studies
(Schulz et al. 2001; Brodkin et al. 2002a), we have dem-
onstrated that MPEP can produce anxiolytic-like effects in
conditioned and unconditioned response models, similar to
the benzodiazepines, and we have extended this finding to
include the newer mGluR5 antagonist, MTEP.
LY456236 also produced anxiolytic-like effects in the
Vogel conflict and CLS models. These data support recent
findings of Klodzinska et al. (2004a), who demonstrated
that the systemic administration of the mGluR1 antagonist,
AIDA, produced anxiolytic-like effects in the elevated
plus maze and Vogel conflict assays. However, in our
study, the anxiolytic effects of LY456236 were smaller in
magnitude, compared to MPEP, MTEP, and CDP. Further-
more, in both models, there was evidence that the 30 mg/
kg dose of LY456236 affected behavior; total licking was
reduced in the Vogel conflict study, and licking during the
unpunished phase of the CLS test was reduced. However,
given the lack of effect of LY456236 on LMA, this might
suggest that the reduced licking following LY456236 is
not due to sedation-like effects and may be related to a
reduced motivation to lick. Further studies are needed to
explore this.
When compounds affect motor coordination or produce
sedation, these effects may confound the interpretation of
data from behavioral studies, including data from the pain
and stress/fear models used in these studies. Spooren et al.
(2000) and Schulz et al. (2001) addressed potential side
effects following the systemic administration of MPEP by
examining spontaneous LMA and reported no significant
effects up to doses of 100 and 30 mg/kg, respectively.
Conversely, Brodkin et al. (2002a) found that MPEP
significantly decreased the rate of responding in the un-
punished component of the Geller–Seifter assay. No data
with LY456236 are available in the literature, although the
mGluR1 antagonist, AIDA, neither induced sedation nor
disturbed motor coordination in rats (Klodzinska et al.
2004a). As secondary effects can influence behavior and
will ultimately determine the potential safety margin for
mGluR antagonists, MPEP, MTEP, and LY456236 were
tested in five assays measuring motor coordination, re-
sponse rate, and body temperature in order to determine
the potential issues with mGluR5 or mGluR1 antagonists
and to establish safety margins. MPEP and MTEP pro-
duced effects in the assays at dose ranges of 10–100 and
1–100 mg/kg, respectively. LY456236 only reduced FR
responding at a dose of 30 mg/kg; there were no effects of
LY456236 in the other four assays up to a dose of 30 mg/
kg. By comparing efficacious doses to doses that affected
secondary behaviors, MPEP and MTEP exhibited little, if
any, window between efficacious doses in the SNL and
Vogel conflict models and doses producing potential side
effects. LY456236, on the other hand, exhibited approxi-
mately a ten-fold window between the antiallodynic and
anxiolytic-like dose and a dose that would potentially
produce side effects. However, it is important to note that
our studies have examined only a limited number of po-
tential side effects. Other potential issues, including effects
on learning and memory, effects on prepulse inhibition
that have been reported with both mGluR1 (Brody et al.
2003) and mGluR5 (Kinney et al. 2003; Brody et al. 2004)
knockout mice, and interactions between mGluR5 antago-
nists and psychomimetics (see Kinney et al. 2003), need to
be addressed further. Furthermore, it will be important to
establish whether mGluR5 and mGluR1 antagonists ex-
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hibit some of the issues associated with the benzodiaze-
pines, particularly tolerance following chronic dosing and
withdrawal syndrome following drug cessation.
Importantly, the full pharmacokinetic profile of LY45
6236 is unknown. The studies of Anderson et al. (2002,
2003) demonstrate a dose proportional occupancy of
mGluR5 receptors within the CNS after intraperitoneal
administration of MPEP and MTEP, with doses of 10 and
3 mg/kg of each, respectively, achieving >75% receptor
occupancy. However, to the best of our knowledge, equi-
valent occupancy data for LY456236 binding to mGluR1
following systemic administration are not available. Ac-
cordingly, it is difficult at the present time to compare the
efficacy and tolerability profile of an mGluR1 antagonist
compared with mGluR5 antagonists. The data of Ander-
son et al. (2002, 2003), together with the present efficacy
data, however, might suggest that, at least in the mGluR5
subclass, there is little separation between anxiolytic and
motor and/or motivational side effects, at least following
an acute dosage. Clearly, a broader range of tool com-
pounds is required to further characterize mGluR5 and
mGluR1.
In conclusion, mGluR5 and mGluR1 antagonists are
effective in rodent models of anxiolysis and nociception.
While mGluR5 antagonists elicit more robust anxiolytic-
like effects compared to the mGluR1 antagonist LY456236,
the opposite may be true for the antinociceptive properties
of these agents. Future studies with antagonists from
structurally diverse chemical series with well-character-
ized pharmacokinetic profiles, as well as studies in alter-
native species, will ultimately test the generality of these
observations.
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